Current clinical research is primarily focused on developing new drugs, such as albumin-bound docetaxel, and studying the efficacy and safety of nab-paclitaxel-based monotherapy or combination therapy as a first- or second-line treatment for advanced gastric cancer. This evidence concerns the gene ALB and gastric cancer.